Study summary
Dato-DXd helped people live about 5 months longer than chemotherapy
23.7months median survival, vs 18.7 with chemotherapy
What was tested
Datopotamab deruxtecan (Dato-DXd), an antibody-drug conjugate aimed at TROP2, against chemotherapy as first treatment for advanced TNBC when immunotherapy was not an option.
What they found
- Median overall survival was 23.7 vs 18.7 months; progression-free survival was 10.8 vs 5.6 months.
- Severe treatment-related side effects were 33% vs 29%.
What it means
A second antibody-drug conjugate with a survival benefit in first-line TNBC.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.